Affimed to Present Data on AFM13 at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland
June 12 2019 - 5:30AM
Heidelberg, Germany, June 12, 2019 – Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, announced today that two abstracts from the Company’s lead
innate cell engager AFM13 have been accepted for oral and poster
presentation at the 15th International Conference on Malignant
Lymphoma (ICML) being held June 18 to 22, 2019 in Lugano,
Switzerland.
Presentations related to AFM13, Affimed’s lead
CD30/CD16A bispecific ROCK® antibody, include a data update of the
completed clinical study of AFM13 in combination with Merck’s
Keytruda® (pembrolizumab) in patients with relapsed or refractory
Hodgkin lymphoma and updated clinical and immunological data from
Columbia University on AFM13 in patients with relapsed or
refractory CD30-positive lymphoma with cutaneous manifestation.
Details for the ICML presentations are as follows:
Oral Presentation:
Abstract: Investigating safety
and preliminary efficacy of AFM13 plus Pembrolizumab in Patients
with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin
FailureSession: 11 – New Drugs
CombinationDate and Time: Saturday, June 22, 8:30
- 10:00 am (CET)Location: Room
A (main hall of Palazzo dei Congressi)
Poster Presentation:
Abstract: Clinical and
Biological Evaluation of the Novel CD30/CD16A Tetravalent
Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive
Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa
Study (NCT03192202)Section: Immunotherapy
Poster sessions: Wednesday, June 19, 12:00 - 17:00
(CET), Thursday, June 20, 9:00 - 17:00 (CET) and Friday, June 21,
9:00 - 18:30 (CET)Location: Marquee Parco
Ciani
Full abstracts of the presentations are
published in the supplement to “Hematological Oncology” (John Wiley
and Sons, Inc.), available on the Wiley Online Library website.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer. Affimed’s fit-for-purpose ROCK®
platform allows innate cell engagers to be designed for specific
patient populations. The Company is developing single and
combination therapies to treat cancers. For more information,
please visit www.affimed.com.
Affimed Investor
Contact:Gregory Gin, Head of Investor RelationsE-Mail:
IR@affimed.com
Affimed Media Contact:Anca
Alexandru, Head of Communications, EU IRE-Mail:
media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024